The Safety and Efficacy of Cerebrolysin in Patients With Acute Ischemic Stroke
Status:
Completed
Trial end date:
2011-02-01
Target enrollment:
Participant gender:
Summary
The study investigated the clinical efficacy and safety of a 10-day course of therapy with
daily intravenous administration of 30mL Cerebrolysin based on a comparison with Placebo in
patients with acute ischemic stroke. 1070 patients were randomized in this trial in 2
parallel groups, one receiving Cerebrolysin, the control group receiving Placebo. Study drug
will be given once daily by intravenous infusion for 10 consecutive days. Acetylsalicylic
acid will be given orally, once daily throughout the study duration of 90 days as basic
treatment. The clinical observation period for each patient will be 3 months and will include
six clinical evaluation visits at Baseline (day 1) and on study days 2, 5, 10, 30 and 90.
Phase:
Phase 4
Details
Lead Sponsor:
Ever Neuro Pharma GmbH
Collaborators:
Excel PharmaStudies, Inc. idv Datenanalyse und Versuchsplanung